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Abstract
Indole derivatives compounds (IDC) are a new class of splicing inhibitors that have a selective action on exonic splicing
enhancers (ESE)-dependent activity of individual serine-arginine-rich (SR) proteins. Some of these molecules have been
shown to compromise assembly of HIV infectious particles in cell cultures by interfering with the activity of the SR protein
SF2/ASF and by subsequently suppressing production of splicing-dependent retroviral accessory proteins. For all
replication-competent retroviruses, a limiting requirement for infection and pathogenesis is the expression of the envelope
glycoprotein which strictly depends on the host splicing machinery. Here, we have evaluated the efficiency of IDC on an
animal model of retroviral pathogenesis using a fully replication-competent retrovirus. In this model, all newborn mice
infected with a fully replicative murine leukemia virus (MLV) develop erythroleukemia within 6 to 8 weeks of age. We tested
several IDC for their ability to interfere ex vivo with MLV splicing and virus spreading as well as for their protective effect in
vivo. We show here that two of these IDC, IDC13 and IDC78, selectively altered splicing-dependent production of the
retroviral envelope gene, thus inhibiting early viral replication in vivo, sufficiently to protect mice from MLV-induced
pathogenesis. The apparent specificity and clinical safety observed here for both IDC13 and IDC78 strongly support further
assessment of inhibitors of SR protein splicing factors as a new class of antiretroviral therapeutic agents.
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Introduction
Retrovirus pathogenesis combines a whole array of mechanisms that
can involve lytic, oncogenic, inflammatory or mutagenic processes that
translate into a variety of diseases, including neoplasia, leukemias,
immunodeficiencies, autoimmune syndromes, anemia, and thrombo-
cytopenia and other hematopoietic disorders, neurodegenerative
diseases and encephalitis, arthritis and osteopetrosis, etc. Murine
leukemia virus (MLV) have been extensively used as models of
retroviral pathogenesis because of the various pathogenic effects that
can be selectively produced in mice. This diverse MLV-induced
pathogenic outcome is dependent on a variety of parameters, including
the virus and mouse strains or the age of infection [1–3]. When injected
into mice of susceptible strains before 3 days of age, fully virulent
strains of the replication-competent Friend MLV (F-MLV) invariably
induce an erythroleukemia (EL) that results in the death of 100%
animals, generally within 2 months after inoculation [4,5].
The earliest phase of the disease has been shown to be directly
dependent on the viral envelope glycoprotein (Env) [4,5], while the
latestphaseinvolvesmorespecificallyretrovirus-mediatedinsertional
mutagenesis governed by transcriptional promoting and enhancing
properties of the U3 sequence in the MLV LTR [5–7]. In all
retroviruses, Env is encoded by the main spliced retroviral mRNA.
Other cis-acting sequences of the MLV genome, such as alternative
or cryptic splice sites, have also been shown to play a specific role in
the F-MLV leukemogenic process [3,8–10]. Therefore, retroviral
RNA metabolism, including transcriptional and splicing stages, is of
paramount importance in the development of retroviral pathogen-
esis, in general, and F-MLV pathogenesis, in particular.
For all replication-competent retroviruses, replication and spread-
ing depend on the production of two major RNA species, a full length
mRNA and a single-spliced mRNA. The full-length mRNA can
either be translated into the capsid Gag and the enzymatic Pol
polyprotein precursors or be packaged into virions as a dimer to
constitute the retroviral genome. The single-spliced mRNA encodes
Env, the virus envelope glycoprotein which interacts with cellular
receptors and which is essential for productive viral entry. Env
expressionistightly dependenton the host splicingmachinery and is a
limiting requirement for virus spreading and pathogenesis. Mutations
that affect MLV canonical or alternative splice sites have been shown
to contribute to inefficient replication and altered pathogenic effects
[3,9,10]. Therefore, inhibiting this single-splicing event offers a
specific way to prevent retroviral spreading and pathogenesis.
Recently, we have reported the identification of several indole
derivatives compounds (IDC) that mediate direct and selective
interactions with members of the serine-arginine rich (SR) protein
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be potent inhibitors of HIV-1 replication in cell culture through a
selective action on exonic splicing enhancers (ESE)-dependent
activity of individual SR proteins [12]. One such molecule, IDC16
has been shown to interfere with the SF2/ASF SR protein and
production of HIV regulatory proteins and to compromise assembly
of infectious particles [13]. However, no evaluation of IDC on
retrovirus-mediated pathogenesis has yet been documented. Here,
wehavetaken advantageoftheF-MLV induced pathogenesismodel
in newborn mice to evaluate the efficiency of this new class of
molecules at different stages of retrovirus infection and disease. We
show now that different IDC differentially inhibit HIV-1 and MLV,
mostlikelyreflecting distinctrequirement for cellularsplicing factors.
Thus, we found that IDC13 and IDC78, but not IDC16, prevented
F-MLV replication both ex vivo and in vivo, by selectively altering
single-splicing of the retroviral genome. Furthermore, we describe
two IDC that also proved to be very efficient at protecting mice from
MLV-induced pathogenesis by inhibiting early viral replication.
Results
IDC that can inhibit ex vivo replication of MLV
We first screened for IDC that could have an effect on ex vivo
replication of MLV. Target murine cells were infected with a
prototypic virulent strain of F-MLV at the low multiplicity of
infection (MOI) of 0.5 focus-forming unit (FFU) per cell in the
presence of various IDC. The number of infected cells was
evaluated 48 h post-infection by flow cytometry, after staining
with the H48 anti-F-MLV Env monoclonal antibody [14]. Among
several IDC tested, IDC13 and IDC78 demonstrated the strongest
inhibitory activity (Fig. 1A and Table S1). Interestingly, IDC16,
which has been shown to inhibit efficiently ex vivo replication of
HIV-1 [13], had a more moderate effect on F-MLV replication,
suggesting that requirements for SR proteins vary with the
retrovirus type.
We further evaluated the efficiency of this inhibition by testing
increasing virus MOI (0.2, 1 and 10 FFU/cell) in the presence of
IDC13, IDC78 or IDC16. In the absence of IDC, increasing MOI
resulted in a non-linear increase in the percentage of infected cells
(close to 100% of cells were infected at a MOI of 10 FFU/cell)
(Fig. 1B). Treatment with IDC13 or IDC78 resulted in a strong
decrease of F-MLV infection at all MOI tested, with up to 95%
inhibition with IDC78 even at the highest MOI. In contrast,
IDC16 did not prevent massive spreading of the virus when
applied with the highest MOI, with a 35% inhibition of virus
infection at the MOI of 10 FFU/cell (Fig. 1B).
The selective and highly most efficient inhibition of MLV
infection observed here in cell culture with IDC13 and IDC78, but
Figure 1. IDC can inhibit ex vivo replication of F-MLV in an MOI-dependent manner. A) Structure and formula of selected IDC compounds.
B) Dunni cells were infected with Friend-MLV (strain 57) at a multiplicity of infection (MOI) of 0.5 foci forming unit (ffu)/cell in the presence of 1 mMo f
various IDC. Cells were stained 48 h post-infection with the H48 anti-F-MLV Env monoclonal antibody and analyzed by flow cytometry. C) Dunni cells
were infected with increasing MOI of F-MLV (0.2, 1 or 10 ffu/cell) in the presence of 1 mM of IDC13, IDC78 or IDC16. Cells were stained 48 h post-
infection with an anti-F-MLV Env antibody and analyzed by flow cytometry. The % of infected cells (i.e. cells stained by anti-Env) is indicated.
doi:10.1371/journal.pone.0004533.g001
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splicing factors by different types of retroviruses.
IDC13 and IDC78 inhibit splicing of the MLV genome
In order to better understand the molecular mechanisms
underlying the specific inhibition of MLV replication by some of
the IDC, we analyzed the viral RNA content of infected cells.
Dunni cells were infected with F-MLV in the presence of different
IDC and total RNA was extracted and used as template for RT-
PCR. We used two different sets of oligonucleotide primers that
allowed us to discriminate between spliced and unspliced viral
RNAs (Fig. 2A). As an internal control, RT-PCR was performed
on mRNA from the gadph house-keeping gene.
Compared to untreated cells, accumulation of the PCR product
corresponding to the spliced F-MLV RNA dramatically decreased
upon treatment with IDC13 and IDC78 (Fig. 2B), while
accumulation of the gapdh product did not decrease. Neither
IDC16, mentioned above, nor IDC217, a compound that had no
effect on all splicing substrates tested [12], had detectable impact
on F-MLV splicing (Fig. 2B). Altogether, these results indicated
that inhibition of F-MLV replication by certain IDC appeared
directly associated with their ability to specifically inhibit viral
RNA splicing, an event required for expression of the viral Env
glycoprotein. However, we observed that the significant decrease
of spliced product observed after IDC13 and IDC78 treatment
was not compensated by a corresponding increase of unspliced F-
MLV RNA. Instead, we noted that IDC13, IDC78 and also
IDC16 affected, albeit to a lesser extent for the latter,
accumulation of unspliced viral RNA (Fig. 2B, lower panel).
These results suggested that IDC13 and IDC78 inhibited F-MLV
replication by altering viral RNA splicing, but that other pathway(s)
governing RNA accumulation, such as transcriptional levels, RNA
trafficking and/or RNA stability, could also be altered.
IDC13 and IDC78 protect mice against F-MLV
pathogenesis
We then examined the impact of IDC treatment on the in vivo
replication and pathogenesis of F-MLV after inoculation of newborn
mice. When injected in susceptible mice strains before the age of
3 days, this virus very reproducibly induces erythroleukemia (EL),
resulting in the death of 100% animals within 2 months [4,15].
In order to evaluate the effect of IDC on MLV-induced EL,
newborn mice were injected with 1 ffu of F-MLV (strain 57) and
treated with IDC13, IDC78 or PBS, used as inoculation control.
The disease parameters that were followed were anemia,
splenomegaly or other organ enlargement, general aspect and
survival. Even though previous reports on F-MLV pathogenesis
used .10
4 FFU/mouse, we show here that a viral input as low as
1 ffu was sufficient to induce EL in newborn mice. Indeed, 100%
of control mice (treated with PBS) developed splenomegaly and
died from EL within 95 days after inoculation of this dose of F-
MLV (Fig. 3). Severe anemia could also be detected in these
animals (data not shown). In contrast, mice treated with
compound IDC13 (n=14) or IDC78 (n=7) showed a significantly
increase in the latency of MLV-induced EL. At the time when all
control mice were dead, IDC-treated mice showed a 50% or 71%
rate of survival, respectively (Fig. 3). Within these two groups,
several mice even survived, without any detectable symptom, up to
506 days before being sacrificed.
IDC13 and IDC78 inhibit in vivo replication of F-MLV
To determine whether the low virulence observed in mice
treated with IDC13 and IDC78 was due to a block of F-MLV in
vivo replication, plasma from treated and non-treated mice were
assayed for early infectious virus content (13 days post-inocula-
tion). The quantification of plasmatic viremia was carried out after
Figure 2. IDC13 and IDC78 alter splicing of F-MLV RNA. A) Schematic structures of integrated proviral DNA and spliced and unspliced F-MLV
RNAs, including the position of the donor (SD) and acceptor (SA) splice sites. Arrows refers to the approximate positions of primers used to selectively
amplify the spliced and unspliced viral product by PCR. Also noted are the gag, pol and env genes products. B) Dunni cells were infected with F-MLV
at an MOI of 10 ffu/cell in the presence of 1 mM of IDC13, IDC78, IDC16 or IDC217. Total RNA was extracted 48 h post-infection, samples were treated
with DNAse to remove any contaminating genomic DNA and used as a template for RT-PCR. Oligonucleotide primers specific for GADPH mRNA were
used as internal control. The lower band migrating faster than spliced RNA (middle panel) corresponds to unhybridized oligos 1+2. The size markers
in bp are indicated on the left of each panel.
doi:10.1371/journal.pone.0004533.g002
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immunostaining assay (FIA) [16].
In control mice, plasmatic viremia 13 days after inoculation
ranged from undetectable to 10
6 ffu/ml, with a mean value of
1.9610
5 ffu/ml (Fig. 4A). Viremia of IDC13-treated mice ranged
between undetectable and 1.6610
5 ffu/ml with a mean value of
3.7610
4 ffu/ml. In IDC78-treated mice, viremia varied between
undetectable and 3610
4 ffu/ml, with the exception of 1 mouse
that had a viremia of 8.4610
5 ffu/ml. Furthermore, we observed
that there was a correlation between a lower plasmatic viremia
and increased latency of disease in IDC-treated mice (data not
shown). Altogether, this indicated that lower virulence of F-MLV,
observed in IDC-treated mice, was likely due to inhibition of virus
replication during the early phase of the disease.
In order to further assess whether resistance to F-MLV-induced
erythroleukemia in IDC-treated mice was indeed due to inhibition of
earlyvirus dissemination, and nottoa toxic effect leadingtoreduction
of target cells, we measured the direct effect of these compounds on
erythroid differentiation in vivo. Newborn mice were injected with
compounds IDC13, IDC78 or IDC217 (or PBS as a negative control)
and followed both for hematocrits between 16 to 21 days of age and
for spleen enlargement as an indication of compensatory splenic
activity. There was no significant difference of either hematocrit or
relative weight values between the 4 groups (Fig. 4B), indicating that
all three IDC, regardless of their virus inhibitory activity, had no
direct detectable effect on erythroid differentiation in mice.
To gain a better understanding of the level of transcript variation
in mice treated with IDC78, we performed a differential analysis of
total splenocyte RNA extracted from IDC-treated mice spleens as
compared to PBS-treated mice. Probes were prepared from pooled
RNA samples to hybridize to ÆÆ Affymetrix GeneChipH Mouse
.Exon 1.0 ST Array ææ. Out of 6000 genes that were detected with
high confidence only 52 showed a gene expression level fold change
(treated vs untreated) comprised between 1.5 and 3 (Figure S1). A
likely explanation for little changes in the expression of endogenous
gene compared to F-MLV could be that the viral RNA has to escape
the splicing machinery during later stages of infection to produce
viral particles containing full length unspliced pre-mRNA, whereas
most cellular genes have constitutive exons that contain redundant
binding sites for SR proteins.
Altogether, our data suggest that some IDC, which are members
of a new class of SR protein inhibitors, can protect animals from
retroviral pathogenesis, partly due to alteration of splicing of the
retroviral genome leading to inhibition of early viral replication.
Discussion
Expression of retroviral proteins, thereby retroviral replication
and spreading, rigorously depends on the splicing of the viral
genome. Here, we identified new IDC that altered splicing of the
retroviral genome and conferred protection from MLV-induced
retroviral pathogenesis. Interestingly, we found that IDC action
could be selective depending on the retrovirus used. Thus, we have
previously shown that IDC16 is a powerful inhibitor of HIV-1
replication assayed in cell cultures [12,13], while here we found it
inefficient at inhibiting MLV replication. Conversely, IDC13 and
IDC78, which have a strong protective effect against F-MLV
pathogenesis, were found to affect neither splicing nor replication
Figure 3. IDC13 and IDC78 protect mice against MLV-induced erythroleukemia. Newborn Swiss mice were injected intra-peritoneally with
F-MLV together with either PBS, IDC13 or IDC78. Development of F-MLV induced erythroleukemia was monitored by occurrence of severe anemia
and splenomegaly. Evaluation of pathogenicity was plotted as % of survival in the different groups. The % of survival in the two groups of IDC treated
mice, at the time when all mice of the untreated group were dead, are indicated.
doi:10.1371/journal.pone.0004533.g003
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can selectively target splicing events essential for the viral life cycle.
While the exact mechanism responsible for the selective impact
of IDC remains to be elucidated, the targeting of SR proteins by
these compounds is likely to involve post-translational steps when
modifications and/or interaction of SR proteins with specific and/
or constitutive splicing factors take place. Indeed, IDC have been
shown ex vivo to bind directly to the RS domain of SR proteins and
thereby impede its phosphorylation. Several IDC have been
shown to prevent phosphorylation of RS domains by topoisom-
erase I and to a lower extent by Clk/Sty kinase, a modification
known to be required for ESE-dependent splicing [17]. It is
therefore possible that the effect of the drug involves modulation of
the phosphorylation status of specific SR proteins. Another
potential level of action of IDC is viral RNA trafficking. In favor
of this is the fact that several SR proteins are able to shuttle
between the nucleus and the cytoplasm [18,19]. This property,
which appears to be linked to the ability of SR proteins to interact
with the nuclear import protein transportin-SR [20,21], is also
regulated by phosphorylation [22]. Since phosphorylation affects
both splicing activity and sub-cellular trafficking of SR proteins
[17], it would be interesting to evaluate the effect of IDC
treatment on SR protein phosphorylation and retroviral RNA
trafficking by SR kinases [11,12,23]. Treatment of cells with IDC
may modulate both processes and act synergistically to modify
MLV RNA splicing and/or export. This dual impact may explain
Figure 4. IDC13 and IDC78 do not significantly affect normal erythropoiesis while inhibiting in vivo F-MLV replication. A) Early
plasmatic viremia was measured in mice infected with F-MLV and treated with each indicated IDC or with PBS. Values indicate the plasmatic virus titer
of individual mice, as measured by infection of Dunni cells by serum dilutions recovered at 16 days of age. Mean values are indicated as a bar for each
group. B) Newborn Swiss mice were injected only with IDC (or PBS as a control) and evaluated between 16 and 21 days of age for indicators of
erythropoiesis, i.e. hematocrit as previously described [5,15] (left panel) and relative spleen weight calculated as (spleen weight/mouse weight)61000
(right panel). For comparison, the values measured for F-MLV injected mice, showing signs of F-MLV induced early anemia, are included in the graphs.
doi:10.1371/journal.pone.0004533.g004
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distinctively observed with IDC13 and 78.
Drugs interfering with the phosphorylation level of SR proteins
and/or interaction with cellular factors are expected to modify the
alternative splicing pattern of several genes. Such drugs which
target most, if not all SR proteins, likely exhibit a significant
cytotoxicity and are therefore less compatible with long term
treatments. Conversely, compounds inactivating SR proteins with
a higher selectivity should prove to be less toxic and more adapted
to treat diseases in which the SR protein to be inactivated is well
characterized. In this respect, it is encouraging that treatment of
newborn mice with several IDC did not detectably alter the
splicing profile of endogenous splenic genes, as revealed by a
comprehensive exon microarray designed to detect alteration of
splicing events (Figure S1). Also, the minimal side effects observed
in our animal model further confirm that IDC, unlike deletion of
the gene encoding SR proteins, are selective for factors or
functions that can apparently be substituted by other SR protein
family members. IDC13 and IDC78 but not IDC16 increased life
expectancy of mouse we tested, whereas SR protein depletion is
detrimental for survival [24]. Therefore, as used here, it is unlikely
that IDC impede constitutive functions of SR proteins in gene
expression, such as mRNA export [18,22,25,26], mRNA stability
[27], stimulation of mRNA translation [26] or maintenance of
genomic stability [28,29].
Despite the fact that IDC were initially selected by ex vivo
experiments performed with very simple splicing substrates [12],
these molecules reveal to inhibit splicing events in vivo with good
specificity. Indeed, some of the IDC we tested have been shown
to be potent inhibitors of HIV-1 production in cells chronically
infected by the virus. Since HIV-1 alternative splicing events are
known to be regulated by several members of the SR proteins
family [30], inhibition of splicing by IDC is a likely mechanism
for the remarkable antiviral activities exhibited by these
molecules in cell culture systems. In agreement with this
prediction, one selected molecule, IDC16, that has been shown
to interfere with ESE activity of the SR protein splicing factor
SF2/ASF, inhibits HIV1 replication of macrophage- and T cell–
tropic laboratory strains, clinical isolates, and strains with high-
level resistance to inhibitors of viral protease and reverse
transcriptase [13]. The study presented here addresses for the
first time the antiretroviral potential of such compounds in an in
vivo model of retroviral replication and potent pathogenic effect
and further confirms the effectiveness of IDC as antiviral agents.
Interestingly, we found that the IDC that exerted the maximum
effect on HIV, lentivirus genus, and MLV, gammaretrovirus
genus, were distinct. It is still unclear whether these differences
were due to the use of a different array of SR proteins involved
in RNA metabolism by gammaretroviruses, which rely mainly on
single-splicing events, or lentiviruses whose replication and
spreading is tightly dependent on multi-splicing events that
govern the formation of key regulatory proteins [31]. Alterna-
tively, distinct cell tropism and tissue distribution for the two
types of viruses may play a role in cell type-specific splicing
events. In this view, the recent description of the cell-specific role
of hnRNPL in alternative splicing of CD45 in activated T cells
[32] brings new clues on potential mechanisms that underlie
cell-specific effects of IDC. Here, we describe a genetically
malleable in vivo model which can help further identification of
SR protein that play a specific role in regulating retroviral
splicing, replication and thereby infection, spreading and
dissemination. Such studies coupled with the testing of IDC
class of inhibitors should help the development of new
therapeutic antiviral agents.
Materials and Methods
Cells
Mus Dunni tail fibroblasts (Dunni cells) were grown as monolayer
cultures in Dulbecco modified Eagle’s medium supplemented with
10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U/
ml penicillin, 100 mg/ml streptomycin and 1% non-essential
amino acids.
Virus stock
The Friend-MLV prototype strain 57 has been reported earlier
[15]. For preparation of viral stocks, supernatants were collected
from chronically infected Dunni cells led to confluent monolayer.
Titration of viral stocks was performed by focal immunostaining
assay (FIA) [16]. Briefly, Dunni cells were infected with serial
dilutions of viral stocks in the presence of polybrene (2 mg/ml).
After 2 days of infection, cells were labeled with the H48 anti-F-
MLV Env monoclonal antibody [14] and the titer was determined
by the number of foci per well, which varies linearly with the viral
input in this assay.
Ex vivo replication assay
Dunni cells were seeded on 96-well plates (5610
3 cells/well) the
day before infection. Cells were infected with F-MLV 57 at an
MOI of 0.2, 1 or 10 ffu/cell in the presence of 1 mM of various
indole derivative compounds and 2 mg/ml of polybrene. Cells
were stained 48 h p.i. with the H48 anti-Env monoclonal antibody
and an anti-mouse IgG serum coupled to FITC (Sigma). Cells
were then detached in PBS-5 mM EDTA and analyzed by flow
cytometry (FACSCalibur, Becton Dickinson).
RNA analysis
Cells were infected with F-MLV 57 at a MOI of 10 ffu/cell and
cultured in 6-well plates for 2 days at 37uC. Cells were washed
twice with phosphate-buffered saline, and total RNA was extracted
from cell pellets with TriReagent (Sigma) according to the
manufacturer’s instructions. The samples were treated with
RNase-free DNase (RQ1, Promega) to remove DNA contamina-
tion. Cellular RNA concentrations were quantitated by measuring
optical absorption at 260 nm.
RT was performed with the first strand cDNA synthesis kit (GE
Healthcare). Five mg of cellular RNA sample were denatured at
65uC for 10 min and chilled for 5 min at 4uC before reverse
transcription was performed for 1 h at 37uCi na1 5ml reaction
volume containing 200 ng of oligo(dT)18, 10 mM deoxynucleo-
side triphosphate (dNTP), 10 mM dithiothreitol DTT, RNase/
DNase-free BSA, RNAguard
TM and recombinant MLV RT.
One-tenth of each reaction mixture was used as the starting
material for the different PCRs.
Two combinations of oligonucleotide pairs were used to detect
specific F-MLV transcripts. The oligonucleotide sequences were as
follow (with the sizes of the amplified products indicated in
parentheses): oligo1 59-CGTGGTCTCGCTGTTCCTTGG-39
and oligo2 59-GCGGACCCACACTGTGTC-39 (259 bp) for
unspliced F-MLV RNA detection and oligo3 59-GATATCGGG-
CCTCGGCCAAG-39 and oligo4 59-AAACAGAGTCCCCGTT-
TTGG-39 (250 bp) for spliced RNA. Primers to amplify GAPDH
were as follows: (sense) 59 -GCTCACTGGCATGGCCTTCCG-
TG-39 and (antisense) 59-TGGAAGAGTGGGAGTTGCTGT-
TGA-39 (200 bp). PCRs were carried out with 0.2 mM dNTP
mix, 3 mM MgCl2, PCR buffer, 1.5 U of Taq DNA polymerase
(InVitrogen) and 200 ng of each of the sense and antisense primers.
Denaturation, annealing, and extension were performed at 94, 58,
and 72uC, respectively. PCRs were performed on a RoboCycler
Splicing and Pathogenesis
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werepreceded bya 5-mindenaturation at94uC and terminated bya
10-min extension at 72uC. Amplified samples were electrophoresed
on agarose gel, stained with ethidium bromide and bands were
quantified by FluorImager.
In Vivo experiments
Newborn OF-1/Swiss mice were injected intra-peritoneally
before 3 days of age with 1 focus-forming unit (ffu) of F-MLV
strain 57 together with either PBS or IDC13 or IDC78 (0,2 mg/g
of weight, diluted in PBS). Mice were subsequently injected with
either PBS or with IDC13 or IDC78 (0,2 mg/g of weight, diluted
in PBS) 6 h after the first injection and every other day during
10 days.
Hematocrit and spleen enlargement, two indicators of
erythroleukemia, were monitored weekly from day 16 of age.
Splenomegaly was monitored by palpation and blood was
collected by retro-orbital puncture on animals anesthetized with
methoxyflurane vapor (isofluorane) to measure their hematocrit.
All animal procedures were carried out according to the
European Communities Council Directive (86/609/EEC) and
Convention (ETS123) issued in 1986. Mice were routinely
monitored for evidence of disease and moribund mice were
sacrificed.
For evaluation of IDC effect on erythropoiesis, three-days old
OF-1/Swiss mice were injected intra-peritoneally with either PBS
or IDC78 (0,2 mg/g of weight, diluted in PBS) and sacrificed at
4 days old. Spleens were dissected out and weighed. Total RNA
from frozen spleens was extracted using the Trizol (according to
the manufacturer instructions) and taken up in 10 mM Tris-HCl
pH 8, 0.1 mM EDTA.
Measurements of viremia in mice
Mice serum was obtained from blood collected on 16 days old
mice by centrifugation at 400 g for 5 min. Viremia was measured
by FIA as described earlier [16]. Briefly, 2610
4 Dunni cells were
plated on 12-well plates and infected the day after with serial
dilutions of mice serum in the presence of 2 mg/ml of polybrene.
Cells were fixed 2 days latter with a 4% solution of paraformal-
dehyde and stained with H48 and a FITC-coupled secondary
antibody as mentioned above. The number of foci, representing
the number of ffu contained in the volume of serum used to
infect Dunni cells, was counted and viremia was calculated in
ffu/ml.
Supporting Information
Table S1 Supplemental data to Figure 1
Found at: doi:10.1371/journal.pone.0004533.s001 (0.05 MB
DOC)
Figure S1 We have used ÆÆ Affymetrix GeneChipH Mouse Exon
1.0 ST Array ææ. The annotated probes are fully described in
http://www.affymetrix.com/. The hybridization procedure and
data analysis are described in https://www.affymetrix.com/
support/downloads/manuals/wt_sensetarget_label_manual.pdf
and http://www.affymetrix.com/support/technical/whitepapers/
exon_alt_transcript_analysis_whitepaper.pdf, respectively. Sketch
normalization was performed using the Expression Console
software from Affymetrix. Background was calculated and
subtracted from main probe intensities using the antigenomic
probes as described (Clark TA, Schweitzer AC, Chen TX, Staples
MK, Lu G, et al. (2007) Discovery of tissue-specific exons using
comprehensive human exon microarrays. Genome Biol. 8(4):
R64.). Bad quality probes including probes with high DAPG p-
value in both experimental conditions were not selected. Gene
expression level mean ratio (treated vs. control) was calculated by
summarizing individual probe ratio and normal law p-values were
calculated with the mean ratio and the corresponding standard
deviation. Only 8 genes were identified with a gene expression
level fold change .2 and with a p-value,0.05. Only 45 were
identified with a gene expression level fold change .1.5 with a p-
value,0.05. They are shown in red in the table.
Found at: doi:10.1371/journal.pone.0004533.s002 (2.75 MB
PDF)
Acknowledgments
We thank all members of our laboratories for their continuous input and
helpful discussions. We are grateful to D. Auboeuf and P. De la Grange for
Affymetrix analysis. Flow cytometry and animal experiments were made
possible by the MRI-RIO imaging platform (GIS-IBISA, Languedoc-
Roussillon) and T&TA core facilities, respectively.
Author Contributions
Conceived and designed the experiments: AK MS JT. Performed the
experiments: AK CJ MP. Analyzed the data: AK CJ MS JT. Contributed
reagents/materials/analysis tools: FMB DSG. Wrote the paper: AK MS
JT.
References
1. Chesebro B, Portis J-L, Wehrly K, Nishio J (1983) Effect of murine host
genotype on MCF virus expression, latency, and leukemia cell type of leukemias
induced by Friend murine leukemia helper virus. Virology 128: 221–233.
2. Peterson K-E, Chesebro B (2006) Influence of proinflammatory cytokines and
chemokines on the neuropathogenesis of oncornavirus and immunosuppressive
lentivirus infections. Curr Top Microbiol Immunol 303: 67–95.
3. Wolff L, Koller R, Bies J, Nazarov V, Hoffman B, et al. (1996) Retroviral
insertional mutagenesis in murine promonocytic leukemias: c-myb and Mml1.
Curr Top Microbiol Immunol 211: 191–199.
4. Sitbon M, Evans L, Nishio J, Wehrly K, Chesebro B (1986) Analysis of two
strains of Friend murine leukemia viruses differing in ability to induce early
splenomegaly: lack of relationship with generation of recombinant mink cell
focus-forming viruses. J Virol 57: 389–393.
5. Sitbon M, d’Auriol L, Ellerbrok H, Andre C, Nishio J, et al. (1991) Substitution
of leucine for isoleucine in a sequence highly conserved among retroviral
envelope surface glycoproteins attenuates the lytic effect of the Friend murine
leukemia virus. Proc Natl Acad Sci U S A 88: 5932–5936.
6. Chatis P-A, Holland C-A, Silver J-E, Frederickson T-N, Hopkins N, et al. (1984)
A3 9 end fragment encompassing the transcriptional enhancers of nondefective
Friend virus confers erythroleukemogenicity on Moloney leukemia virus. J Virol
52: 248–254.
7. Mikkers H, Berns A (2003) Retroviral insertional mutagenesis: tagging cancer
pathways. Adv Cancer Res 88: 53–99.
8. Audit M, Dejardin J, Hohl B, Sidobre C, Hope T-J, et al. (1999) Introduction of
a cis-acting mutation in the capsid-coding gene of moloney murine leukemia
virus extends its leukemogenic properties. J Virol 73: 10472–10479.
9. Dejardin J, Bompard-Marechal G, Audit M, Hope TJ, Sitbon M, et al. (2000) A
novel subgenomic murine leukemia virus RNA transcript results from alternative
splicing. J Virol 74: 3709–3714.
10. Sorensen A-B, Lund A-H, Kunder S, Quintanilla-Martinez L, Schmidt J, et al.
(2007) Impairment of alternative splice sites defining a novel gammaretroviral
exon within gag modifies the oncogenic properties of Akv murine leukemia virus.
Retrovirology 4: 46.
11. Tazi J, Durand S, Jeanteur P (2005) The spliceosome: a novel multi-faceted
target for therapy. Trends Biochem Sci 30: 469–478.
12. Soret J, Bakkour N, Maire S, Durand S, Zekri L, et al. (2005) Selective
modification of alternative splicing by indole derivatives that target serine-
arginine-rich protein splicing factors. Proc Natl Acad Sci U S A 102: 8764–
8769.
13. Bakkour N, Lin YL, Maire S, Ayadi L, Mahuteau-Betzer F, et al. (2007) Small-
molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy
to overcome drug resistance. PLoS Pathog 3: 1530–1539.
Splicing and Pathogenesis
PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e453314. Chesebro B, Wehrly K, Cloyd M, Britt W, Portis J, et al. (1981) Characterization
of mouse monoclonal antibodies specific for Friend murine leukemia virus-
induced erythroleukemia cells: friend-specific and FMR-specific antigens.
Virology 112: 131–144.
15. Sitbon M, Sola B, Evans L, Nishio J, Hayes SF, et al. (1986) Hemolytic
anemia and erythroleukemia, two distinct pathogenic effects of Friend
MuLV: mapping of the effects to different regions of the viral genome. Cell
47: 851–859.
16. Sitbon M, Nishio J, Wehrly K, Lodmell D, Chesebro B (1985) Use of a focal
immunofluorescence assay on live cells for quantitation of retroviruses:
distinction of host range classes in virus mixtures and biological cloning of
dual-tropic murine leukemia viruses. Virology 141: 110–118.
17. Soret J, Tazi J (2003) Phosphorylation-dependent control of the pre-mRNA
splicing machinery. Prog Mol Subcell Biol 31: 89–126.
18. Huang Y, Gattoni R, Stevenin J, Steitz JA (2003) SR splicing factors serve as
adapter proteins for TAP-dependent mRNA export. Mol Cell 11: 837–843.
19. Caceres J-F, Screaton GR, Krainer A-R (1998) A specific subset of SR proteins
shuttles continuously between the nucleus and the cytoplasm. Genes Dev 12:
55–66.
20. Allemand E, Dokudovskaya S, Bordonne R, Tazi J (2002) A conserved
Drosophila transportin-serine/arginine-rich (SR) protein permits nuclear import
of Drosophila SR protein splicing factors and their antagonist repressor splicing
factor 1. Mol Biol Cell 13: 2436–2447.
21. Kataoka N, Bachorik JL, Dreyfuss G (1999) Transportin-SR, a nuclear import
receptor for SR proteins. J Cell Biol 145: 1145–1152.
22. Huang Y, Yario T-A, Steitz J-A (2004) A molecular link between SR protein
dephosphorylation and mRNA export. Proc Natl Acad Sci U S A 101:
9666–9670.
23. Soret J, Gabut M, Tazi J (2006) SR proteins as potential targets for therapy.
Prog Mol Subcell Biol 44: 65–87.
24. Graveley BR (2000) Sorting out the complexity of SR protein functions. RNA 6:
1197–1211.
25. Huang Y, Steitz JA (2001) Splicing factors SRp20 and 9G8 promote the
nucleocytoplasmic export of mRNA. Mol Cell 7: 899–905.
26. Sanford J-R, Gray N-K, Beckmann K, Caceres J-F (2004) A novel role for
shuttling SR proteins in mRNA translation. Genes Dev 18: 755–768.
27. Lemaire R, Prasad J, Kashima T, Gustafson J, Manley JL, et al. (2002) Stability
of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a
novel function for SR proteins. Genes Dev 16: 594–607.
28. Li X, Manley J-L (2005) Inactivation of the SR protein splicing factor ASF/SF2
results in genomic instability. Cell 122: 365–378.
29. Xiao R, Sun Y, Ding J-H, Lin S, Rose D-W, et al. (2007) Splicing regulator
SC35 is essential for genomic stability and cell proliferation during mammalian
organogenesis. Mol Cell Biol 27: 5393–5402.
30. Ropers D, Ayadi L, Gattoni R, Jacquenet S, Damier L, et al. (2004) Differential
effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of
the A1 to A5 splicing sites of HIV-1 RNA. J Biol Chem 279: 29963–29973.
31. Anderson J-L, Hope T-J (2004) HIV accessory proteins and surviving the host
cell. Curr HIV/AIDS Rep 1: 47–53.
32. Oberdoerffer S, Moita L-F, Neems D, Freitas R-P, Hacohen N, et al. (2008)
Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein,
hnRNPLL. Science 321: 686–691.
Splicing and Pathogenesis
PLoS ONE | www.plosone.org 8 February 2009 | Volume 4 | Issue 2 | e4533